XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue [1] $ 639,653 $ 427,690
Expenses    
Cost of revenue [1] 535,547 310,475
Selling, general and administrative expenses [1] 79,104 89,726
Depreciation and amortization expenses 29,503 29,275
Change in fair value of contingent consideration 8,908 8,569
Total operating expenses 653,062 438,045
Operating loss (13,409) (10,355)
Interest income 2,550 1,060
Interest expense (5,997) (12,895)
Gain from equity method investees 306 423
Change in tax receivables agreement liability (173) (66,184)
Other income (expense), net 8 (220)
Loss before income taxes (16,715) (88,171)
Provision for (benefit from) income taxes 565 (68,189)
Loss before preferred dividends and accretion of Series A Preferred Stock (17,280) (19,982)
Dividends and accretion of Series A Preferred Stock (7,945) (6,276)
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic (25,225) (26,258)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (25,225) $ (26,258)
Basic and diluted    
Basic (in dollars per share) $ (0.22) $ (0.24)
Diluted (in dollars per share) $ (0.22) $ (0.24)
Weighted-average common shares outstanding    
Basic (in shares) 114,141 107,783
Diluted (in shares) 114,141 107,783
Comprehensive loss    
Net loss attributable to common shareholders of Evolent Health, Inc. $ (25,225) $ (26,258)
Other comprehensive loss, net of taxes, related to:    
Foreign currency translation adjustment (51) 56
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. $ (25,276) $ (26,202)
[1] See Note 18 for amounts attributable to unconsolidated related parties included in these line items.